A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

Recently, combined therapy with androgen deprivation therapy and androgen receptor pathway inhibitors has been recommended for metastatic hormone-sensitive prostate cancer patients.

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966. [ 2 ] ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

The need to balance the oncological benefits of androgen deprivation therapy (ADT) with patient quality of life (QOL) outcomes has investigators from around the world calling for both careful ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Results: Few immune cells were detected in the needle biopsies before androgen deprivation therapy. After androgen deprivation therapy, prostatectomy specimens showed a significant change in various ...

Adding local external beam radiation therapy (EBRT) to androgen deprivation therapy (ADT) reduces the rate of prostate cancer-related adverse events among patients with synchronous bone metastatic ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...